Israel Englander’s Oncternal Therapeutics, Inc. Common Stock ONCT Stock Holding History

Israel Englander’s Portfolio ONCT Stock Details ONCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-714	Closed	-$157K	–	4293
2018 Q3	$157K	Buy	+714	New	+$1.71M	﹤0.01%	3681
2013 Q3	–	Sell	-151	Closed	-$1.39M	–	3643
2013 Q2	$1.39M	Buy	+151	New	+$1.16M	﹤0.01%	1795

Other funds holding ONCT

SPIA

Steward Partners Investment Advisory New York $19.6B AUM 29.84% 1-Year Est. Return

NRG

Nemes Rush Group Novi, Michigan $1.21B AUM 33.22% 1-Year Est. Return

Israel Englander's ONCT Position: Q4 2024 in Review

Israel Englander sold out of Oncternal Therapeutics, Inc. Common Stock (ONCT) in Q4 2024, closing a stake of 61,205 shares — an estimated $80.8K sold.

Israel Englander first reported a position in ONCT in Q2 2013 and held it in 33 quarters. The position peaked at $3.29M in Q1 2021. 4 funds tracked by Wall St. Rank hold ONCT as of Q4 2024.

Israel Englander reported no remaining Oncternal Therapeutics, Inc. Common Stock position as of Q4 2024 after selling out during the quarter.
Israel Englander sold 61,205 Oncternal Therapeutics, Inc. Common Stock shares in Q4 2024, an estimated $80.8K.
Israel Englander first reported a position in Oncternal Therapeutics, Inc. Common Stock in Q2 2013 and held it in 33 quarters.
Israel Englander's Oncternal Therapeutics, Inc. Common Stock position peaked at $3.29M in Q1 2021.
4 funds tracked by Wall St. Rank held Oncternal Therapeutics, Inc. Common Stock as of Q4 2024.

Based on Millennium Management's 13F filing for Q4 2024, filed 14 Feb 2025.